Regional and System Planning Sample Clauses

Regional and System Planning. Corridor Overview
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Regional and System Planning. State Planning Regional Planning
Sample 1Sample 2See All (4)
Regional and System Planning. The proposed modifications by this project are consistent with regional and local planning, as discussed below.
Sample 1Sample 2
Regional and System Planning. SR 1 is a north-south route that begins in Capistrano Beach in Orange County and runs intermittently up the State of California where it ends at SR 101 in Leggett in Mendocino County. In Santa Xxxxxxx and San Xxxx Obispo Counties it is primarily a two-lane conventional highway that lies within mostly agricultural land. In and near the project, SR 1 runs through agricultural land except at the south end where the roadway lies within the northern limits of the City of Xxxxxxxxx. Within the project limits, SR 1 is classified as Conventional Highway. The latest Transportation Concept Report (TCR), prepared in 2019, for SR 1 in District 5 indicates that this area is functionally classified as rural and a Major Arterial. In long stretches, for example, a few miles north and south of the Santa Xxxxxxx/San Xxxx Obispo County line, the route is a Minor Arterial. The route designations are Interregional Road System, California Legal Truck Network, and Pacific Coast Bicycle Route. Within the City of Xxxxxxxxx, a disadvantaged community, SR 1 serves as “Main Street” and has Class II bicycle lanes, is a route for local and regional transit service, and the downtown AMTRAK station is accessed from SR1. This project is consistent with the Transportation Concept Report 2019. It recommends that the bridge project increase shoulder widths where needed, including on bridge crossing to improve motor vehicle, bicyle and pedestrian operations and safety. The project scope is also consistent with the City of Guadalupe’s 2020 Mobility and Revitalization Plan. It addresses the city’s vision for improved multimodal transportation in this vicinity. Extensive community engagement activities were conducted during development of the Plan which was funded by a Caltrans Sustainable Transportation Planning Grant. Caltran’s District 5 staff participated in community engagement activities. The City of Guadalupe’s 2020 Mobility and Revitalization Plan identifies the need to fill gaps in the pedestrian and bicycle network, improve the safety and comfort of all users that encourages walking and bicycling, and increase connectivity, mobility and accessibility within the community of Xxxxxxxxx to key destinations along and near the downtown corridor including businesses, restaurants, AMTRAK station, transit stops, local schools, community parks, and City government offices. This plan did extensive outreach effort to get massive input from the community including Advisory group meetings, walking ...
Sample 1Sample 2
Regional and System Planning. SR 119 is a major East West connector starting from SR 33 in Taft to SR 99 in Bakersfield. It passes through some of Xxxx County's most famous oil fields, including the Midway-Sunset, the third-largest oil field in the United States; the Buena Vista Oil Field; and runs adjacent to the Elk Hills Oil Field. Land use along SR 119 include commercial and residential development, as well as oil fields and agriculture in the rural county area. The route also passes through the City of Xxxx, and small communities of Ford City, Valley Acres, Xxxxxx Acres, and Pumpkin Center. SR 119, as identified in the Transportation Concept Report (TCR), is on the Freeway and Expressway System and is considered a Terminal Access route on the STAA Truck Network. It is a route with Regional Significance. SR 119 serves as the main connector between the extreme southwestern corner of the San Xxxxxxx Valley and Bakersfield. SR 119 is a two-lane conventional highway and is planned to be a six-lane expressway in the vicinity of the project, in keeping with City of Bakersfield and County of Xxxx General Plan Circulation Elements. Per the 2009 Xxxx County General Plan Circulation Element, SR 119 connects Taft to Bakersfield. Near Taft, SR 119 passes directly through Valley Acres and Xxxxxx Acres. The 2009 General Plan has a Goal to realign and upgrade SR 119 from SR 99 to west of Taft, with a Policy stating Caltrans should upgrade SR 119 to a freeway – a project to include construction of a bypass around the communities of Xxxxxx Acres and Valley Acres. The plan further qualifies this policy by stating Caltrans should bring this project to a “ready stage”, with the Roads Department coordinating with Caltrans in developing and updating a Route Concept Report and Project Study Report for the facilities. Similarly, both Xxxx Council of Governments (KCOG) and the Xxxx County Roads Department should coordinate with Caltrans in developing Federal Transportation Improvement Plan (FTIP) priorities for SR 119 freeway. Note an update of the Xxxx County General Plan is currently underway. KCOG’s 2018 Regional Transportation Plan (RTP) includes in Chapter 2 Planning Policy 16.1 to widen SR 119 in the vicinity of Taft. KCOG considers SR 119 to be regionally significant and in Xxxx County it is also known as Xxxx Highway. SR 119 has been a part of a KCOG-commissioned truck origin-destination study (in 2011), and the bypass portion of a project to widen SR 119 from Cherry Avenue to Elk Hills Road was re...
Sample 1Sample 2
Regional and System Planning. In alignment with Caltrans’ mission and the purpose of the State’s Stra- tegic Highway Safety Plan (SHSP) which is expected to provide a safe transportation system, the District System Management Plan (DSMP) provides working guidelines aiming to enhance a safer, more sustaina- ble, integrated and efficient transportation system. The DSMP states that continued addition of roadway capacity alone is not a viable so- lution to address congestion issues. Other efforts are needed such as investments in multimodal infrastructure as well as transportation xx- xxxx management. In preparation for future mobility demands based on trends for housing, population, job growth, and finance, the 2020 SHOPP Asset Manage- ment Program refined project prioritization parameters, incorporated the Caltrans Strategic Management Plan. Under the 2020 SHOPP cycle that replaced the program specific funding allocation with a lump sum structure that incentivizes multi-objective projects. The project aims to improve mobility and provide efficient traffic move- ment and safety for one of the most congested segments on I-405, providing upgrades and improvement to the existing facilities, includ- ing the pavement and roadside safety improvements. Coordination among many other on-going projects on I-405 that over- lap the project limits is critical to successfully deliver the project on schedule and within budgets. Minimizing conflicts on scopes between projects requires direct coordination between each project team. Ad- ditionally, future projects frequently have multiple alternatives under study, each with differing scope and schedule. Continuous coordina- tion and collaboration with the following project should be in focus: 1. Multi-Asset Management Project (EA 0R330) proposes to perform cold plane and overlay of existing GP lanes on I-405 from Harbor Blvd to XxXxxxxx Ave. (PM 11.4/16.9)
Sample 1Sample 2
Regional and System Planning i. Identify Systems I-80 and US 50, within the project limits, are designated as the Interstate Systems on the National Highway Systems (NHS). I-80 is a transcontinental interstate facility critical to regional and interregional transportation. I- 80 serves as the only freeway connection between the San Francisco Bay Area and the Sacramento metropolitan region. As previously mentioned, I-80 is recognized as one of the Top 6 Corridors per SB 671’s XXX truck routes. The I-80 and US 50 also link the Bay Area with recreational destinations in the Sierra Nevada Mountains and points north via I-505 to I-5. The I-80 and US 50 corridors are a crucial part of the Northern California freight industry as they connect to I-5 and create the most northern interregional freight hub in California. Neither I-80 nor US. 50 are classified as scenic highways. Both I-80 and US. 50 are National Network Routes (STAA) for trucks with no special restrictions. 1 Throughput is the number of people moving efficiently through a region.
Sample 1
AutoNDA by SimpleDocs
Regional and System Planning. I-80 is a primary freeway that serves interregional travel between the San Francisco Bay Area, Sacramento, and Nevada. The work on I-80 is in Segments 2 and 3 of the 2017 I-80 Transportation Concept Report (TCR). Segment 2 is a six-lane freeway from the Xxxx Boulevard Interchange, PM 2.68, to I-80/US 50 Separation, PM 9.55. Segment 3 is six-lane freeway from the I-80/US 50 Separation, PM 9.55, to the Yolo/Sacramento County Line, PM R11.718. Segment 2 operated at Level of Service (LOS) F and Segment 3 operated at LOS C in the year 2014 and will both have a LOS E in 2035. US 50 serves the large Sacramento metropolitan area up to just east of Placerville, where it primarily serves recreational travel to the Sierra Nevada and Lake Tahoe. The work on US 50 is in Segment 1 of the 2014 US 50 Transportation Concept Report (TCR) and Corridor System Management Plan (CSMP). Segment 1 is from the I-80/US 50 Separation, PM 0.0, to the Yolo/Sacramento County Line, PM 3.16. The existing facility is an eight-lane freeway and the ultimate facility consists of 8 general purpose lanes, 2 High Occupancy Vehicle (HOV) lanes, Auxiliary lanes, as well as Intelligent Transportation System (ITS) and Intelligent Corridor Management (ICM) elements. Segment 1 operated at LOS E in the year 2012 and will have a LOS F in 2035. Other projects that are in or near this project are listed below:
Sample 1
Regional and System Planning 
Sample 1Sample 2Sample 3

Related to Regional and System Planning

  • Project Planning GOVERNMENTAL APPROVALS; ENVIRONMENTAL COMPLIANCE; PUBLIC INFORMATION 30 4.1 Planning and Engineering Activities 30 4.2 Site Conditions 30 4.3 Governmental Approvals 30 4.4 Environmental Compliance 34 4.5 Community Outreach and Public Information 35

  • Sales and Marketing Subdistributor shall market, promote, and solicit orders for the Products to prospective and existing Customers (excluding the Excluded Customers) consistent with good business practice and the highest professional standards in the industry, in each case using its best efforts to maximize Product sales volume in the Territory in accordance with Distributor’s Product marketing strategies, channel and pricing guidelines, and sales policies, and in a manner that reflects favorably at all times on the Products and the good name, goodwill, and reputation of Distributor;

  • Training and Professional Development 11.1 The Employer will develop and maintain an employee training and development plan and provide such plan to the Union upon request. Staff training is intended to provide an opportunity for classified staff employees for training sponsored by the University Training and Development and the UW Medical Centers Organizational Development and Training. Education/Professional Leave is intended to facilitate employee access to continuing education opportunities. Training and educational/professional leave may be used for the purpose of improving job performance, maintaining and increasing proficiency, preparing staff for greater responsibility, or increasing promotional opportunities within the framework of staff positions available at the University. 11.2 Any release time for training for employees accepted for such classes shall be in accordance with the Executive Order (currently No. 52) governing this matter. In the event that two or more employees request the same training period and supervision must limit the number of persons who may participate at one time due to work requirements, the selection will be made on a mutually agreeable basis within the department. 11.3 The training program is a proper subject for discussion by either departmental or University-wide Joint Union/Management Committees. 11.4 If the Employer requires an employee to receive training, reimbursement will be provided in accordance with the University travel rules. Employee attendance at Employer required training, either during or outside working hours, will be considered time worked and compensated in accordance with the provisions of this Agreement. 11.5 Employee attendance at training not required by the Employer and not covered by Executive Order 52, either on approved leave from or outside of working hours, will be voluntary and not considered time worked.

  • Strategic Planning Facilitate the effective alignment of IT requirements/ Information Resource Management (IRM) plans with strategic business plans and program initiatives. Management Improvements: Development and implementation of improved systems and business practices to optimize productivity and service delivery operations (e.g., analysis, and implementation of improvements in the flow of IT work and program processes and tool utilization, including business system analysis, identification of requirements for streamlining, re-engineering, or re-structuring internal systems/business processes for improvement, determination of IT solution alternatives, benchmarking).

  • Statistical and Marketing-Related Data All statistical or market-related data included or incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources, to the extent required.

  • Procurement Planning Prior to the issuance of any invitations to bid for contracts, the proposed procurement plan for the Project shall be furnished to the Association for its review and approval, in accordance with the provisions of paragraph 1 of Appendix 1 to the Guidelines. Procurement of all goods and works shall be undertaken in accordance with such procurement plan as shall have been approved by the Association, and with the provisions of said paragraph 1.

  • Transition Planning The AGENCY will be responsible for the development of the student’s Transition Plan, which begins upon entry and is completed prior to the student’s exit.

  • Training and Promotion a. The contractor will assist in locating, qualifying, and increasing the skills of minorities and women who are applicants for employment or current employees. Such efforts should be aimed at developing full journey level status employees in the type of trade or job classification involved. b. Consistent with the contractor's work force requirements and as permissible under Federal and State regulations, the contractor shall make full use of training programs, i.e., apprenticeship, and on-the-job training programs for the geographical area of contract performance. In the event a special provision for training is provided under this contract, this subparagraph will be superseded as indicated in the special provision. The contracting agency may reserve training positions for persons who receive welfare assistance in accordance with 23 U.S.C. 140(a). c. The contractor will advise employees and applicants for employment of available training programs and entrance requirements for each. d. The contractor will periodically review the training and promotion potential of employees who are minorities and women and will encourage eligible employees to apply for such training and promotion.

  • Regulatory Affairs From the point in time at which Novartis gives GW notice in writing that it wishes to take on responsibility for Regulatory Filings and Regulatory Approvals in the Territory, Novartis shall be responsible for all interactions with Regulatory Authorities in the Territory with respect to Regulatory Approvals as set forth in this Section 6.1, and including, filing and maintaining any required Regulatory Approvals, seeking necessary permits and/or scheduling or re-scheduling in controlled substance listings or de-scheduling of the Product from controlled substances listings in the Territory. (a) Where required, Novartis (or its applicable Affiliate or Sublicensee) will be responsible for arranging for the Product to be scheduled in any applicable controlled substance schedule(s) in countries in the Territory. GW agrees, without additional consideration, to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing and to provide Novartis with all assistance reasonably requested by Novartis (including attending meetings with Regulatory Authorities in any such country) for the purpose of arranging for such scheduling. (b) Subject to Section 6.1(g), Novartis (or its applicable Affiliate or Sublicensee) will file and hold all Regulatory Approvals for the Products in countries in the Territory in its own name and on its own behalf. Unless otherwise agreed by the Parties, within ten (10) Business Days following the Effective Date, GW will assign to Novartis all Regulatory Filings with any Regulatory Authority in the Territory at the Effective Date relating to any Product and Novartis will reimburse GW all fees paid by GW to Regulatory Authorities in such countries with respect to the submission of such Regulatory Filings. On request by Novartis, GW will deliver notices of such assignment to the applicable Regulatory Authorities. In addition, GW agrees to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing. (c) Subject to Sections 4.2 and 6.1(e), Novartis (or its applicable Affiliate or Sublicensee) will be responsible for conducting, at its sole expense, such activities directed towards obtaining and maintaining Regulatory Approvals for Products in the Territory as it determines appropriate in its sole discretion; provided, however, that Novartis agrees to submit Regulatory Filings for Marketing Approvals for a Product in each of the Key Countries. Thereafter, Novartis shall, on a Key Country-by-Key Country basis further prosecute all such Regulatory Filings in the Key Countries in a timely, professional and diligent manner, including by paying all required filing fees promptly and responding to correspondence and requests for further information from Regulatory Authorities in the Key Countries within a reasonable timeframe. Novartis shall share with GW its plans for obtaining Regulatory Approvals in the Key Countries at the first JSC meeting and thereafter shall supply GW with its updated plan from time to time. Novartis shall report its performance against this regulatory plan to the JSC each Calendar Quarter. (d) Novartis will: (A) determine the regulatory plans and strategies for the Products in the Territory; (B) (either itself or through its Affiliates or Sublicensees and subject to Section 6.1(g)) make and own all Regulatory Filings with respect to the Products in the Territory; and (C) will be responsible for obtaining and maintaining Regulatory Approvals with respect to the Products in the Territory in the name of Novartis or its Affiliates or Sublicensees. Accordingly: (i) Novartis, shall at its own cost write, assemble, otherwise prepare and file all Regulatory Filings required to obtain Regulatory Approvals for Products in the Territory; (ii) Novartis shall be the principal contact with all Regulatory Authorities on all matters pertaining to any Product, but shall consult regularly with GW regarding such matters, giving due regard to GW’s views; (iii) Novartis shall provide to GW copies of all substantive correspondence with Regulatory Authorities in the Territory related to any Product, and, to the extent practicable, shall consult with GW in advance of submitting any material correspondence related to any Product to any such Regulatory Authority; (iv) GW shall provide to Novartis copies of all substantive correspondence with the EMA related to any Product and, to the extent practicable, shall consult with Novartis in advance of submitting any material correspondence related to any Product to the EMA in circumstances where such correspondence could reasonably be expected to impact on the Commercialization and/or Regulatory Approvals of any Product in the Territory; (v) Novartis shall provide such notice to GW as is reasonably practicable under the circumstances of upcoming meetings related to any Product with Regulatory Authorities in the Territory. Subject to the consent of the relevant Regulatory Authority, GW shall be entitled to attend any such meetings as an observer, and Novartis may require GW’s attendance at any such meeting it deems to be potentially material; and (vi) Novartis shall pay all filing and maintenance costs of Regulatory Filings and Regulatory Approvals for the Product in the Territory during the Term. (e) GW shall, without additional consideration, fully cooperate with and provide assistance to Novartis in connection with filings to any Regulatory Authority relating to the Product(s) in the Territory in order to obtain or maintain Regulatory Approvals (including Pricing and/or Reimbursement Approvals, where applicable), including by (i) providing Novartis with an electronic copy of the registration dossier for the Product in the European Union as well as providing Novartis with an electronic copy of this registration dossier in eCTD format if and when available in eCTD format, and upon request by Novartis, an electronic copy of a draft of the registration dossier for the Product in the US as soon as such draft is made available to GW (if this draft is made available to GW in eCTD format GW will provide it to Novartis in eCID format); (ii) upon request by Novartis, providing Novartis with draft responses to any requests from Regulatory Authorities in the Territory related to the Development or manufacture of Products (including any requests related to the chemistry manufacturing and controls (CMC) section of any Regulatory Filing); and (iii) executing any required documents, providing access to personnel and providing Novartis with copies of all reasonably required documentation. To the extent requested by Novartis, GW shall also grant or cause to be granted to Novartis and its Affiliates or Sublicensees, within thirty (30) days of receipt of a written request from Novartis, cross-reference rights to any relevant drug master files and other filings submitted by GW or its Affiliates with any Regulatory Authority and any Regulatory Approval for Product issued by any Regulatory Authority to GW or its Affiliates. (f) Subject to Novartis having access to reimbursement data from outside the Territory, data generated by Novartis for reimbursement shall be available for GW and its ex-Territory licensees of the Products to use with respect to the Products outside the Territory. (g) In the event that (A) it is not possible under applicable Laws for Novartis to file for or hold Regulatory Approvals for the Product in any country in the Territory and/or (B) if requested by Novartis in writing to do so, to the extent permitted by applicable Laws and for the duration determined by Novartis, GW will file and/or hold all Regulatory Approvals for the Products in such country, at Novartis’s cost and expense (provided that all such costs and expenses shall be in accordance with a plan and budget agreed in writing by the Parties prior to GW making any such Regulatory Filing), and: (i) GW will be responsible for, and will use diligent efforts in, obtaining and maintaining all Regulatory Approvals necessary for the Commercialization of the Products in the country in question; (ii) GW will provide to Novartis copies of all substantive written communications between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product; (iii) Novartis shall have the right to review and comment upon any Regulatory Filings and correspondence from GW (or its Affiliates) to any Regulatory Authority in the Territory relating to any Product, and GW shall incorporate or address all such comments unless otherwise agreed between the Parties; (iv) GW will request and seek to arrange such meetings and consultations with Regulatory Authorities in the Territory which may be requested by Novartis, with respect to any Product; (v) To the extent permitted by the relevant Regulatory Authorities, Novartis shall have the right to have representatives of Novartis attend and participate in all meetings between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product; it being understood and agreed that to the extent permitted by the relevant Regulatory Authorities, Novartis will lead discussions with any such Regulatory Authority in the Territory. If the applicable Regulatory Authority does not permit Novartis to lead any such discussion, GW will lead the applicable discussions as directed by Novartis; and (vi) Novartis will reimburse GW any and all costs incurred pursuant to the foregoing and in accordance with the agreed plan and budget as follows. Within thirty (30) days after each Calendar Quarter during which GW has incurred any such costs and expenses, GW will provide to Novartis a detailed accounting of all such costs and expenses, and shall submit an invoice to Novartis substantially in the form of Exhibit C with respect to the amount of such costs and expenses. Unless disputed, Novartis shall pay such amount within sixty (60) days after receipt of such invoice. (h) Novartis hereby grants, and undertakes to cause its Affiliates and Sublicensees to grant, to GW and its Affiliates cross-reference rights to any Regulatory Filing for Product submitted by Novartis or its Affiliates or Sublicensees to any Regulatory Authority in the Territory and any Marketing Approval for Product issued by any Regulatory Authority in the Territory to Novartis or its Affiliates or Sublicensees. Novartis shall also grant such cross-reference rights to those of GW’s licensees of the Products for countries outside the Territory for which Novartis, its Affiliates and Sublicensees are granted corresponding cross-reference rights. (i) The Parties will discuss at the JSC the appropriate response to any request received by either Party from a Third Party academic institution to conduct any investigator initiated clinical study of a Product in the Territory. (j) If any information comes into GW’s Control that requires a change to the CMC section of Regulatory Filings or Regulatory Approvals, inside and outside the Territory, to avoid ‘regulatory drift’ GW will inform Novartis in writing of the required change (including by providing the necessary technical documentation in English) and Novartis will file such documentation with the relevant Regulatory Authorities as soon as practicable.

  • Curriculum Development This includes the analysis and coordination of textual materials; constant review of current literature in the field, some of which are selected for the college library collection, the preparation of selective, descriptive materials such as outlines and syllabi; conferring with other faculty and administration on curricular problems; and, the attendance and participation in inter and intra-college conferences and advisory committees.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!